These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29058821)

  • 21. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
    de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
    Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
    Ring A; Rathgen K; Stangier J; Reilly P; Clemens A; Friedman J
    Clin Drug Investig; 2013 May; 33(5):333-42. PubMed ID: 23519576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
    Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
    Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Eluxadoline Effect on Cardiac Repolarization.
    Bonifacio L; Hunt TL; McIntyre G; Dove LS; Covington PS
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):727-736. PubMed ID: 29659201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study.
    Masters JC; Shaik N; Mendes da Costa L; Hee B; LaBadie RR
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):272-282. PubMed ID: 32790066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
    Spyker DA; Voloshko P; Heyman ER; Cassella JV
    J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects.
    Taubel J; Ferber G; Lorch U; Batchvarov V; Savelieva I; Camm AJ
    Br J Clin Pharmacol; 2014 Jan; 77(1):170-9. PubMed ID: 23713767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
    Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
    Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
    Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
    Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
    Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
    Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
    Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
    Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
    Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
    Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.